Patents Assigned to KCL Therapeutics, Inc.
  • Publication number: 20220249436
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.
    Type: Application
    Filed: March 18, 2022
    Publication date: August 11, 2022
    Applicant: KCL THERAPEUTICS, INC
    Inventors: Harry M. Lander, David R. Koos
  • Patent number: 11324719
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 10, 2022
    Assignee: KCL Therapeutics, Inc.
    Inventors: Harry M. Lander, David R. Koos
  • Patent number: 11241427
    Abstract: Disclosed are compounds useful for alteration of NR2F6 activity. In some embodiments of the invention compounds disclosed are utilized for stimulation of NR2F6 activity, alone, or in combination with PKC activation. In other embodiments, the invention teaches use of compounds for inhibition of NR2F6 activation. Stimulation of NR2F6 within the context of the invention is useful, intra alia, for induction of immune inhibition, or stimulation of cellular proliferation without significant induction of differentiation. Inhibition of NR2F6 is desired in situations where the practitioner of the invention seeks to augment immune response, or induce cellular differentiation. In another embodiment, inhibition of NR2F6 expression is desired in situations where inhibition of cancer or cancer stem cells is needed.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 8, 2022
    Assignee: KCL Therapeutics, Inc.
    Inventors: David Koos, Thomas Ichim